Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event

Endocrine

Volumn 47, Issue 1, 2014, Pages 138-145

  Huh, Ji Hye ^a   Seok, Hannah ^a   Lee, Byung Wan ^a   Kang, Eun Seok ^a   Lee, Hyun Chul ^a   Cha, Bong Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cilostazol; Intima media thickness (IMT); Lipid profile; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; CILOSTAZOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SARPOGRELATE; TRIACYLGLYCEROL; TRIFLUSAL; ANTITHROMBOCYTIC AGENT; TETRAZOLE DERIVATIVE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG USE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; CARDIOVASCULAR DISEASES; CAROTID ARTERY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; DRUG EFFECTS; ECHOGRAPHY; MIDDLE AGED; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 84906935988     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0120-y     Document Type: Article

References (29)

1. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339(4), 229-234 (1998)
2. P. Koskinen, M. Manttari, V. Manninen, J.K. Huttunen, O.P. Heinonen, M.H. Frick, Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 15(7), 820-825 (1992)
3. R. Kawamori, Y. Yamasaki, H. Matsushima, H. Nishizawa, K. Nao, H. Hougaku, H. Maeda, N. Handa, M. Matsumoto, T. Kamada, Prevalence of carotid atherosclerosis in diabetic patients. Ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 15(10), 1290-1294 (1992)
4. T.J. Smilde, S. van Wissen, H. Wollersheim, M.D. Trip, J.J. Kastelein, A.F. Stalenhoef, Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577-581 (2001)
5. M.W. Lorenz, H.S. Markus, M.L. Bots, M. Rosvall, M. Sitzer, Prediction of clinical cardiovascular events with carotid intimamedia thickness: a systematic review and meta-analysis. Circulation 115(4), 459-467 (2007)
6. M.R. Langenfeld, T. Forst, C. Hohberg, P. Kann, G. Lubben, T. Konrad, S.D. Fullert, C. Sachara, A. Pfutzner, Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111(19), 2525-2531 (2005)
7. E. Lonn, S. Yusuf, V. Dzavik, C. Doris, Q. Yi, S. Smith, A. Moore-Cox, J. Bosch, W. Riley, K. Teo, S. Investigators, Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103(7), 919-925 (2001)
8. B. Hedblad, J. Wikstrand, L. Janzon, H. Wedel, G. Berglund, Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 103(13), 1721-1726 (2001)
9. J. Kambayashi, Y. Liu, B. Sun, Y. Shakur, M. Yoshitake, F. Czerwiec, Cilostazol as a unique antithrombotic agent. Curr. Pharm. Des. 9(28), 2289-2302 (2003)
10. Y. Han, Y. Li, S. Wang, Q. Jing, Z. Wang, D. Wang, Q. Shu, X. Tang, Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am. Heart J. 157(4), 733-739 (2009)
11. H. Ota, M. Eto, M.R. Kano, S. Ogawa, K. Iijima, M. Akishita, Y. Ouchi, Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28(9), 1634-1639 (2008)
12. S.Y. Park, H.K. Shin, J.H. Lee, C.D. Kim, W.S. Lee, B.Y. Rhim, K.W. Hong, Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J. Pharmacol. Exp. Ther. 329(2), 571-579 (2009)
13. D.F. Geng, J. Deng, D.M. Jin, W. Wu, J.F. Wang, Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis 220(1), 177-183 (2012)
14. C.M. Ahn, S.J. Hong, J.H. Park, J.S. Kim, D.S. Lim, Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessel 26(5), 502-510 (2011)
15. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1), S62-S69 (2010)
16. J.H. Moon, M.K. Chae, K.J. Kim, H.M. Kim, B.S. Cha, H.C. Lee, Y.J. Kim, B.W. Lee, Decreased endothelial progenitor cells and increased serum glycated albumin are independently correlated with plaque-forming carotid artery atherosclerosis in type 2 diabetes patients without documented ischemic disease. Circ. J. 76(9), 2273-2279 (2012)
17. S.K. Kim, S.W. Park, S.H. Kim, B.S. Cha, H.C. Lee, Y.W. Cho, Visceral fat amount is associated with carotid atherosclerosis even in type 2 diabetic men with a normal waist circumference. Int. J. Obes (Lond) 33(1), 131-135 (2009)
18. P.J. Touboul, M.G. Hennerici, S. Meairs, H. Adams, P. Amarenco, N. Bornstein, L. Csiba, M. Desvarieux, S. Ebrahim, M. Fatar, R. Hernandez, M. Jaff, S. Kownator, P. Prati, T. Rundek, M. Sitzer, U. Schminke, J.C. Tardif, A. Taylor, E. Vicaut, K.S. Woo, F. Zannad, M. Zureik, Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the advisory board of the 3rd and 4th watching the risk symposium, 13th and 15th european stroke conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc. Dis 23(1), 75-80 (2007)
19. G.K. Hansson, Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685-1695 (2005)
20. American Diabetes Association, Standards of medical care in diabetes - 2011. Diabetes Care 34 (Suppl 1), S11-S61 (2011)
21. N. Katakami, Y.S. Kim, R. Kawamori, Y. Yamasaki, The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 121(23), 2584-2591 (2010)
22. S.U. Kwon, Y.J. Cho, J.S. Koo, H.J. Bae, Y.S. Lee, K.S. Hong, J.H. Lee, J.S. Kim, Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter doubleblind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36(4), 782-786 (2005)
23. A.K. Kamal, I. Naqvi, M.R. Husain, B.A. Khealani, Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst. Rev. (1), CD008076 (2011)
24. M. Rizzo, E. Corrado, A.M. Patti, G.B. Rini, D.P. Mikhailidis, Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin. Pharmacother. 12(4), 647-655 (2011)
25. H. Ueno, H. Koyama, Y. Mima, S. Fukumoto, S. Tanaka, T. Shoji, M. Emoto, T. Shoji, Y. Nishizawa, M. Inaba, Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. J. Atheroscler. Thromb. 18(10), 883-890 (2011)
26. V.J. Dzau, R.C. Braun-Dullaeus, D.G. Sedding, Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8(11), 1249-1256 (2002)
27. M.A. Feijge, K. Ansink, K. Vanschoonbeek, J.W. Heemskerk, Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem. Pharmacol. 67(8), 1559-1567 (2004)
28. N.K. Agrawal, R. Maiti, D. Dash, B.L. Pandey, Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol. Res. 56(2), 118-123 (2007)
29. T. Wada, Y. Onogi, Y. Kimura, T. Nakano, H. Fusanobori, Y. Ishii, M. Sasahara, H. Tsuneki, T. Sasaoka, Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions. Eur. J. Pharmacol. 707(1-3), 120-129 (2013)